Ginsenoside F1
(Synonyms: 人参皂苷 F1; 20(S)-Ginsenoside F1) 目录号 : GN10032
Ginsenoside F1是从人参中提取的次级代谢产物，是人参皂苷Rg1的脱糖衍生物。
Cas No.:53963-43-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ginsenoside F1 is a secondary metabolite extracted from ginseng and is a desugared derivative of ginsenoside Rg1 [1]. Ginsenoside F1 promotes NK cell cytotoxic activity through an insulin-like growth factor-1-dependent mechanism [2]. Ginsenoside F1 is mainly used to treat cancer and inflammation [3].
In Human umbilical vein endothelial cells (HUVECs), Ginsenoside F1 (20, 40μM; 24h) promotes the proliferation, migration and invasion of HUVECs [4]. In HEK293 cells, Ginsenoside F1 (50, 100, 200µg/mL; 4h) significantly suppressed the proliferation of B16 melanoma up to 60% at 200µg/mL [5]. In HaCat cells, Ginsenoside F1 (1, 5, 10, 50μM; 24h) protects HaCat cells from UVB-induced apoptosis [6]. In SH-SY5Y cells, Ginsenoside F1 (2.5, 5, 10μM; 24h) Reduces Aβ1–42-induced cytotoxicity in neuronal cells [7].
In Alzheimer’s disease (AD) model mice, Ginsenoside F1 (20mg/kg; po; 8 weeks) improves memory function in APPswe/PSEN1dE9 (APP/PS1) double-transgenic AD model mice [8]. In high fat diet induced ApoE-/- atherosclerosis mice, Ginsenoside F1 (50mg/kg; ig; 8 weeks) improves endothelial cell inflammatory injury and prevents atherosclerosis in mice via A20-mediated inhibition of NF-kB signaling [9]. In ob/ob mice, administration of ginsenoside F1 (60mg/kg; ig; 5 weeks) augments thermogenesis to lower blood glucose and lipid [10].
References:
[1]. Meragelman TL, Renteria BS, Silva GL, et al. Modified secoiridoid from Acicarpha tribuloides and inhibition of nitric oxide production in LPS-activated macrophages. Phytochemistry. 2006 Jul 1; 67(14): 1534-1538.
[2]. Kwon HJ, Lee H, Choi GE, et al. Ginsenoside F1 promotes cytotoxic activity of NK cells via insulin-like growth factor-1-dependent mechanism. Frontiers in Immunology. 2018 Nov 28; 9: 2785.
[3]. Li J, Li F, Jin D. Ginsenosides are promising medicine for tumor and inflammation: A review. The American journal of Chinese medicine. 2023 Apr 17; 51(04): 883-908.
[4]. Zhang J, Liu M, Huang M, et al. Ginsenoside F1 promotes angiogenesis by activating the IGF-1/IGF1R pathway. Pharmacological Research. 2019 Jun 1; 144: 292-305.
[5]. Yoo DS, Rho HS, Lee YG, et al. Ginsenoside F1 modulates cellular responses of skin melanoma cells. Journal of Ginseng Research. 2011; 35(1): 86-91.
[6]. Lee EH, Cho SY, Kim SJ, et al. Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2. Journal of investigative dermatology. 2003 Sep 1; 121(3): 607-613.
[7]. Yun YJ, Park BH, Hou J, et al. Ginsenoside F1 protects the brain against amyloid beta-induced toxicity by regulating IDE and NEP. Life. 2022 Jan 1; 12(1): 58.
[8]. Han J, Oh JP, Yoo M, et al. Minor ginsenoside F1 improves memory in APP/PS1 mice. Molecular Brain. 2019 Dec; 12: 1-8.
[9]. Qin M, Luo Y, Lu S, et al. Ginsenoside F1 ameliorates endothelial cell inflammatory injury and prevents atherosclerosis in mice through A20-mediated suppression of NF-kB signaling. Frontiers in Pharmacology. 2017 Dec 22; 8: 953.
[10]. Meng Y, Li W, Hu C, et al. Ginsenoside F1 administration promotes UCP1-dependent fat browning and ameliorates obesity-associated insulin resistance. Food Science and Human Wellness. 2023 Nov 1; 12(6): 2061-2072.
Ginsenoside F1是从人参中提取的次级代谢产物，是人参皂苷Rg1的脱糖衍生物 [1]。Ginsenoside F1通过胰岛素样生长因子1依赖的机制促进NK细胞的细胞毒活性 [2]。Ginsenoside F1主要用于治疗癌症和炎症 [3]。
在人脐静脉内皮细胞（HUVEC）中，Ginsenoside F1（20、40μM；24h）可促进HUVEC的增殖、迁移和侵袭 [4]。在HEK293细胞中，Ginsenoside F1（50、100、200μg/mL；4h）在200μg/mL浓度下显著抑制了B16黑色素瘤的增殖，最高抑制率为60% [5]。在HaCat细胞中，Ginsenoside F1（1、5、10、50μM；24h）可保护HaCat细胞免受UVB诱导的细胞凋亡 [6]。在SH-SY5Y细胞中，Ginsenoside F1（2.5、5、10μM；24h）可降低Aβ1-42诱导的神经元细胞毒性 [7]。
在阿尔茨海默病（AD）模型小鼠中，Ginsenoside F1（20mg/kg；po；8周）可改善APPswe/PSEN1dE9（APP/PS1）双转基因AD模型小鼠的记忆功能 [8]。在高脂饮食诱导的ApoE-/-动脉粥样硬化小鼠中，Ginsenoside F1（50 mg/kg；ig；8周）可通过A20介导的NF-kB信号抑制改善内皮细胞炎症损伤，预防小鼠动脉粥样硬化 [9]。在ob/ob小鼠中，给予Ginsenoside F1（60 mg/kg；ig；5周）可增强产热作用，从而降低血糖和血脂 [10]。
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Preparation Method | The effect of Ginsenoside F1 on the proliferation of HUVECs was measured using the EdU cell proliferation assay. Briefly, HUVECs or HBMECs (3 × 103 cells/well) were seeded in 96-well plates and cultured overnight. Then, the cells were treated with Ginsenoside F1 (20 and 40μM) for 24h, according to the standard protocol of the EdU cell proliferation kit. |
Reaction Conditions | 20, 40μM; 24h |
Applications | Ginsenoside F1 promotes the proliferation, migration and invasion of HUVECs. |
| Animal experiment [2]: | |
Animal models | Alzheimer’s disease (AD) model mice |
Preparation Method | To test the effect of Ginsenoside F1 on AD, Ginsenoside F1 was orally administrated via gelatin-based jelly at a dose level of 20mg/kg/day. For a 1-d dose of jelly, 0.6mg of Ginsenoside F1 was dissolved in 0.45mL of 20% Splenda solution. Ginsenoside F1 solution was further mixed with 1.35mL of 14% gelatin, 20% Splenda solution, and 0.15mL chocolate-flavoring in a 24-well plate. A piece of jelly (~ 1.9mg) was provided, and complete intake of jelly was confirmed daily. |
Dosage form | 20mg/kg; po; 8 weeks |
Applications | Ginsenoside F1 improves memory function in APPswe/PSEN1dE9 (APP/PS1) double-transgenic AD model mice. |
References: | |
| Cas No. | 53963-43-2 | SDF | |
| 别名 | 人参皂苷 F1; 20(S)-Ginsenoside F1 | ||
| 化学名 | (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-[(2R)-6-methyl-2-[(6R,10R,12S,13R,14R,17S)-3,6,12-trihydroxy-4,4,10,14,17-pentamethyl-2,3,5,6,7,8,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol | ||
| Canonical SMILES | CC(=CCCC(C)(C1(CCC2(C1C(CC3C2CC(C4C3(CCC(C4(C)C)O)C)O)O)C)C)OC5C(C(C(C(O5)CO)O)O)O)C | ||
| 分子式 | C36H62O9 | 分子量 | 638.87 |
| 溶解度 | ≥ 31.95mg/mL in DMSO with ultrasonic | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5653 mL | 7.8263 mL | 15.6526 mL |
| 5 mM | 0.3131 mL | 1.5653 mL | 3.1305 mL |
| 10 mM | 0.1565 mL | 0.7826 mL | 1.5653 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet